ERBB2 and non-small cell lung carcinoma: In the DESTINY-Lung01 trial, T-DXd achieved an ORR of 55%, PFS of 8.2 months, and median OS of 17.8 months in 91 patients with ERBB2-mutated NSCLC [80] (Table 8), highlighting a major therapeutic advancement.